BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 2021. [PMID: 34002066 DOI: 10.1038/s41577-021-00547-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol 2022;13:927153. [PMID: 35757715 DOI: 10.3389/fimmu.2022.927153] [Reference Citation Analysis]
2 Li H, Wu X, Bu D, Wang L, Xu X, Wang Y, Liu Y, Zhu P. Recombinant jurkat cells (HMGN2-T cells) secrete cytokines and inhibit the growth of tumor cells. J Mol Histol 2022. [PMID: 35861945 DOI: 10.1007/s10735-022-10084-8] [Reference Citation Analysis]
3 Stein-Merlob AF, Ganatra S, Yang EH. T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies. Heart Fail Clin 2022;18:443-54. [PMID: 35718418 DOI: 10.1016/j.hfc.2022.02.008] [Reference Citation Analysis]
4 Balagopal S, Sasaki K, Kaur P, Nikolaidi M, Ishihara J. Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy. J Mater Chem B 2022. [PMID: 35912720 DOI: 10.1039/d2tb00592a] [Reference Citation Analysis]
5 Alcantara M, Fuentealba J, Soussain C. Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma. Cancers (Basel) 2021;13:5061. [PMID: 34680209 DOI: 10.3390/cancers13205061] [Reference Citation Analysis]
6 Chen L, Xu N, Wang P, Zhu H, Zhang Z, Yang Z, Zhang W, Guo H, Lin J. Nanoalbumin–prodrug conjugates prepared via a thiolation‐and‐conjugation method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting CD8+ T‐cell infiltration. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10377] [Reference Citation Analysis]
7 Shalabi H, Nellan A, Shah NN, Gust J. Immunotherapy Associated Neurotoxicity in Pediatric Oncology. Front Oncol 2022;12:836452. [PMID: 35265526 DOI: 10.3389/fonc.2022.836452] [Reference Citation Analysis]
8 Boettcher M, Joechner A, Li Z, Yang SF, Schlegel P. Development of CAR T Cell Therapy in Children-A Comprehensive Overview. J Clin Med 2022;11:2158. [PMID: 35456250 DOI: 10.3390/jcm11082158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhang Y, Li S, Wang Y, Lu Y, Xu Y, Rao Q, Wang H, Xing H, Tian Z, Tang K, Lv L, Wang M, Wang J. A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy. Exp Hematol Oncol 2022;11:15. [PMID: 35317863 DOI: 10.1186/s40164-022-00270-5] [Reference Citation Analysis]
10 St-Denis-Bissonnette F, Khoury R, Mediratta K, El-Sahli S, Wang L, Lavoie JR. Applications of Extracellular Vesicles in Triple-Negative Breast Cancer. Cancers (Basel) 2022;14:451. [PMID: 35053616 DOI: 10.3390/cancers14020451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Spanjaart AM, van der Valk FM, van Rooijen G, Brouwer MC, Kersten MJ. Confused about Confusion. N Engl J Med 2022;386:80-7. [PMID: 34986289 DOI: 10.1056/NEJMcps2114818] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Uckun FM, Watts J, Mims AS, Patel P, Wang E, Shami PJ, Cull E, Lee C, Cogle CR, Lin TL. Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. Cancers (Basel) 2021;13:5287. [PMID: 34771451 DOI: 10.3390/cancers13215287] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Burton LB, Eskian M, Guidon AC, Reynolds KL. A review of neurotoxicities associated with immunotherapy and a framework for evaluation. Neurooncol Adv 2021;3:v108-20. [PMID: 34859238 DOI: 10.1093/noajnl/vdab107] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Costa LJ, Hungria V, Mohty M, Mateos MV. How I treat triple-class refractory multiple myeloma. Br J Haematol 2022. [PMID: 35373352 DOI: 10.1111/bjh.18185] [Reference Citation Analysis]
15 Chang Y, Syahirah R, Wang X, Jin G, Torregrosa-Allen S, Elzey BD, Hummel SN, Wang T, Li C, Lian X, Deng Q, Broxmeyer HE, Bao X. Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy. Cell Rep 2022;40:111128. [PMID: 35858579 DOI: 10.1016/j.celrep.2022.111128] [Reference Citation Analysis]
16 Ackley J, Ochoa MA, Ghoshal D, Roy K, Lonial S, Boise LH. Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. Cancers (Basel) 2021;13:4787. [PMID: 34638271 DOI: 10.3390/cancers13194787] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Liu S, Nguyen K, Park D, Wong N, Wang A, Zhou Y, Cui Y. Harnessing natural killer cells to develop next‐generation cellular immunotherapy. Chronic Diseases and Translational Medicine. [DOI: 10.1002/cdt3.40] [Reference Citation Analysis]
18 Huang CW, Tsai CH, Lin CW. Optic neuropathy after chimeric antigen receptor T-cell therapy. J Formos Med Assoc 2021:S0929-6646(21)00492-7. [PMID: 34753628 DOI: 10.1016/j.jfma.2021.10.020] [Reference Citation Analysis]
19 Watchmaker PB, Colton M, Pineo-Cavanaugh PL, Okada H. Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma. Curr Opin Oncol 2022. [PMID: 35855503 DOI: 10.1097/CCO.0000000000000877] [Reference Citation Analysis]
20 Burns I, Gwynne WD, Suk Y, Custers S, Chaudhry I, Venugopal C, Singh SK. The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues. Front Oncol 2022;12:815726. [PMID: 35155252 DOI: 10.3389/fonc.2022.815726] [Reference Citation Analysis]
21 Ding M, Fan Y, Lv Y, Liu J, Yu N, Kong D, Sun H, Li J. A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy. Acta Biomater 2022:S1742-7061(22)00380-4. [PMID: 35779775 DOI: 10.1016/j.actbio.2022.06.041] [Reference Citation Analysis]
22 Bhojwani D, Bansal R, Wayne AS. Managing therapy-associated neurotoxicity in children with ALL. Hematology Am Soc Hematol Educ Program 2021;2021:376-83. [PMID: 34889354 DOI: 10.1182/hematology.2021000269] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Shao L, Pelayo A, Shi R, Ma J, Liu H, Cai Y, Prochazkova M, Somerville RP, Panch SR, Shah NN, Stroncek DF, Jin P. Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases. J Transl Med 2022;20:338. [PMID: 35902861 DOI: 10.1186/s12967-022-03531-3] [Reference Citation Analysis]
24 Leclercq G, Steinhoff N, Haegel H, De Marco D, Bacac M, Klein C. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. OncoImmunology 2022;11:2083479. [DOI: 10.1080/2162402x.2022.2083479] [Reference Citation Analysis]
25 Sun Q, Melino G, Amelio I, Jiang J, Wang Y, Shi Y. Recent advances in cancer immunotherapy. Discov Onc 2021;12. [DOI: 10.1007/s12672-021-00422-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Miao L, Zhang J, Zhang Z, Wang S, Tang F, Teng M, Li Y. A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021. Front Immunol 2022;13:840956. [DOI: 10.3389/fimmu.2022.840956] [Reference Citation Analysis]
27 Dixon ML, Leavenworth JD, Leavenworth JW. Lineage Reprogramming of Effector Regulatory T Cells in Cancer. Front Immunol 2021;12:717421. [PMID: 34394124 DOI: 10.3389/fimmu.2021.717421] [Reference Citation Analysis]
28 Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-sanea MM, Althobaiti H. Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Front Bioeng Biotechnol 2022;10:797440. [DOI: 10.3389/fbioe.2022.797440] [Reference Citation Analysis]
29 Baumeister SHC, Mohan GS, Elhaddad A, Lehmann L. Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. Front Oncol 2022;12:841117. [DOI: 10.3389/fonc.2022.841117] [Reference Citation Analysis]
30 Angenendt L, Mikesch J, Schliemann C. Emerging antibody-based therapies for the treatment of acute myeloid leukemia. Cancer Treatment Reviews 2022;108:102409. [DOI: 10.1016/j.ctrv.2022.102409] [Reference Citation Analysis]
31 Leclercq G, Servera LA, Danilin S, Challier J, Steinhoff N, Bossen C, Odermatt A, Nicolini V, Umaña P, Klein C, Bacac M, Giusti A, Schneider A, Haegel H. Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. OncoImmunology 2022;11:2039432. [DOI: 10.1080/2162402x.2022.2039432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Dunai C, Collie C, Michael BD. Immune-Mediated Mechanisms of COVID-19 Neuropathology. Front Neurol 2022;13:882905. [DOI: 10.3389/fneur.2022.882905] [Reference Citation Analysis]
33 Hu T, Tang C, Stern S, Yang L, Du T. 17α-Hydroxyprogesterone Caproate Inhibits Cytokine Production via Suppression of NF-κB Activation. Front Pharmacol 2022;13:831315. [PMID: 35330839 DOI: 10.3389/fphar.2022.831315] [Reference Citation Analysis]
34 Valeri A, García-ortiz A, Castellano E, Córdoba L, Maroto-martín E, Encinas J, Leivas A, Río P, Martínez-lópez J. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Front Immunol 2022;13:953849. [DOI: 10.3389/fimmu.2022.953849] [Reference Citation Analysis]
35 Dai Z, Zhu PF, Liu H, Li XC, Zhu YY, Liu YY, Shi XL, Chen WD, Liu YP, Zhao YL, Zhao LX, Liu HY, Luo XD. Discovery of potent immune-modulating molecule taccaoside A against cancers from structures-active relationships of natural steroidal saponins. Phytomedicine 2022;104:154335. [PMID: 35858515 DOI: 10.1016/j.phymed.2022.154335] [Reference Citation Analysis]
36 Ferreira LMR, Muller YD. CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles' Heel? Front Immunol 2021;12:766220. [PMID: 34868017 DOI: 10.3389/fimmu.2021.766220] [Reference Citation Analysis]
37 Gu T, Hu K, Si X, Hu Y, Huang H. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment. WIREs Mech Dis 2022;:e1576. [PMID: 35871757 DOI: 10.1002/wsbm.1576] [Reference Citation Analysis]
38 Ferreras C, Fernández L, Clares-Villa L, Ibáñez-Navarro M, Martín-Cortázar C, Esteban-Rodríguez I, Saceda J, Pérez-Martínez A. Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours. Cells 2021;10:2940. [PMID: 34831165 DOI: 10.3390/cells10112940] [Reference Citation Analysis]
39 Xiao BF, Zhang JT, Zhu YG, Cui XR, Lu ZM, Yu BT, Wu N. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. Front Immunol 2021;12:782775. [PMID: 34790207 DOI: 10.3389/fimmu.2021.782775] [Reference Citation Analysis]
40 Zhang Q, Xiao Y. [Mechanism and prevention strategies of neurotoxicity in CAR-T treatment of B cell tumors]. Zhonghua Xue Ye Xue Za Zhi 2021;42:787-92. [PMID: 34753239 DOI: 10.3760/cma.j.issn.0253-2727.2021.09.016] [Reference Citation Analysis]
41 Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 2022. [PMID: 34997230 DOI: 10.1038/s41571-021-00588-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 24.0] [Reference Citation Analysis]
42 Uckun FM. Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma. Front Oncol 2021;11:760382. [PMID: 34858838 DOI: 10.3389/fonc.2021.760382] [Reference Citation Analysis]
43 Akbari P, Katsarou A, Daghighian R, van Mil LW, Huijbers EJ, Griffioen AW, van Beijnum JR. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022. [DOI: 10.1016/j.bbcan.2022.188701] [Reference Citation Analysis]
44 Corkill DJ, Hunt AN, Hinrichs MJ, White N, Rebelatto M, Roskos L, Nys J, Scott A, Robinson MJ, Ryan P, Postle AD, Sleeman MA. Chronic pharmacological antagonism of the GM-CSF receptor in mice does not replicate the pulmonary alveolar proteinosis phenotype but does alter lung surfactant turnover. Clin Sci (Lond) 2021;135:2559-73. [PMID: 34778899 DOI: 10.1042/CS20210713] [Reference Citation Analysis]
45 Elazar A, Chandler NJ, Davey AS, Weinstein JY, Nguyen JV, Trenker R, Cross RS, Jenkins MR, Call MJ, Call ME, Fleishman SJ. De novo-designed transmembrane domains tune engineered receptor functions. Elife 2022;11:e75660. [PMID: 35506657 DOI: 10.7554/eLife.75660] [Reference Citation Analysis]
46 Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C, Blumenberg V, Hoster E, Bullinger L, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Barba P, Jain MD, Subklewe M. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer 2022;10:e004475. [PMID: 35580927 DOI: 10.1136/jitc-2021-004475] [Reference Citation Analysis]
47 Wu C, Xu J, Xie Z, Huang H, Li N, Wei X, Li T, Yang H, Li S, Qin X, Liu Y. Light-responsive hyaluronic acid nanomicelles co-loaded with an IDO inhibitor focus targeted photoimmunotherapy against "immune cold" cancer. Biomater Sci 2021;9:8019-31. [PMID: 34718362 DOI: 10.1039/d1bm01409a] [Reference Citation Analysis]
48 Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst AM, Chan YH, Aminkeng F, Bharwani LD, Huang Y, Mak A, Wong ASC. Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature. Front Immunol 2022;13:807050. [PMID: 35154124 DOI: 10.3389/fimmu.2022.807050] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]